• P. N. Patsalos


Carbamazepine (Fig. 1) corresponds chemically to 5H-dibenz[b,f]azepine-5-carboxamide with an empirical formula of C15H12N2O and a molecular weight of 236.27.


Valproic Acid Active Metabolite Pharmacokinetic Interaction Epoxide Hydrolase Pharmacodynamic Interaction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Forsythe WI, Owens JR, Toothill C. Effectiveness of acetazolamide in the treatment of carbamazepine-resistant epilepsy in children. Dev Med Child Neurol. 1981;23:761–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Genton P, Nguyen VH, Mesdjian E. Carbamazepine intoxication and negative myoclonus after the addition of clobazam. Epilepsia. 1998;39:1115–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Johannessen SI, Strandjord RE, Munthe-Kaas AW. Lack of effect o clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine. Acta Neurol Scand. 1977;55:506–12.PubMedCrossRefGoogle Scholar
  4. 4.
    Elger C, Halasz P, Maia J, Almeidas L, Soares-da-Silva P, on behalf of the BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50:454–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Almeida L, Bialer M, Soares-da-Silva P. Eslicarbazepine acetate. In: Shorvon SD, Perucca E, Engel J, editors. The treatment of epilepsy. 3rd ed. Oxford: Blackwell Publishing; 2009. p. 485–98.CrossRefGoogle Scholar
  6. 6.
    Altafullah I, Talwar D, Loewenson R, Olson K, Lockman LA. Factors influencing serum levels of carbamazepine and carbamazepine-10,11-epoxide in children. Epilepsy Res. 1989;4:72–80.PubMedCrossRefGoogle Scholar
  7. 7.
    Wagner ML, Remmel RP, Graves NM, Leppik IE. Effect of felbamate on carbamazepine and its metabolites. Clin Pharmacol Ther. 1993;53:536–43.PubMedCrossRefGoogle Scholar
  8. 8.
    Radulovic LL, Wilder BJ, Leppik IE, Bockbrader HN, Chang T, Posvar EL, Sedman AJ, Uthman BM, Erdman GR. Lack of interaction of gabapentin with carbamazepine and valproate. Epilepsia. 1994;35:155–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol. 2010;50:459–71.PubMedCrossRefGoogle Scholar
  10. 10.
    Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav. 2011;20:20–3.PubMedCrossRefGoogle Scholar
  11. 11.
    Malminiemi K, Keranen T, Kerttula T, Moilanen E, Ylitalo P. Effects of short-term lamotrigine on pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther. 2000;38:540–5.PubMedGoogle Scholar
  12. 12.
    Besag FM, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia. 1998;39:183–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Gidal BE, Baltes E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from the randomized clinical trials. Epilepsy Res. 2005;64:1–11.PubMedCrossRefGoogle Scholar
  14. 14.
    Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res. 2002;48:217–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Browne TR, Feldman RG, Buchanan RA, Allen CA, Fawcett-Vickers L, Szabo GK, Mattson GF, Norman SE, Greenblatt DJ. Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. Neurology. 1983;33:414–8.PubMedCrossRefGoogle Scholar
  16. 16.
    McKee PJW, Blacklaw J, Forrest G, Gillham RA, Walker SM, Connelly D, Brodie MJ. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol. 1994;37:27–32.PubMedCrossRefGoogle Scholar
  17. 17.
    Rambeck B, May T, Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 1987;9:298–303.PubMedCrossRefGoogle Scholar
  18. 18.
    Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, Hounslow NJ, Bron NJ, Gibson GL, Bockbrader HN. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005;46:1407–13.PubMedCrossRefGoogle Scholar
  19. 19.
    Ferron GM, Sachdeo R, Partiot A, Fritz T, Althouse S, Troy SM. Pharmacokinetic interaction between valproic acid, topiramate, phenytoin or carbamazepine and retigabine in epileptic patients. Clin Pharmacol Ther. 2001;63(Suppl 2):18.Google Scholar
  20. 20.
    Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123–41.PubMedCrossRefGoogle Scholar
  21. 21.
    Cazali N, Tran A, Treluyer JM, Rey E, d’Athis P, Vincent J, Pons G. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003;56:526–36.PubMedCrossRefGoogle Scholar
  22. 22.
    Gustavson LE, Cato A, Boellner SW, Cao GX, Quian JX, Guenther HJ, Sommerville KW. Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin. Am J Ther. 1998;5:9–16.PubMedCrossRefGoogle Scholar
  23. 23.
    Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1996;37:774–80.PubMedCrossRefGoogle Scholar
  24. 24.
    Mack CJ, Kuc S, Mulcrone SA, Pilley A, Grunewald RA. Interaction between topiramate and carbamazepine: two case reports and a review of clinical experience. Seizure. 2002;11:464–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Pisani F, Caputo M, Fazio A, Oteri G, Russo M, Spina E, Perucca E, Bertilsson L. Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic interaction. Epilepsia. 1990;31:339–42.PubMedCrossRefGoogle Scholar
  26. 26.
    McKee PJW, Blacklaw J, Butler E, Gillham RA, Brodie MJ. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res. 1992;11:193–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Brodie MJ, Mumford JP. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group. Epilepsy Res. 1999;34:199–205.PubMedCrossRefGoogle Scholar
  28. 28.
    Sanchez-Alcaraz A, Quintana MB, Lopez E, Rodriguez I, Llopis P. Effect of vigabatrin on the pharmacokinetics of carbamazepine. J Clin Pharm Ther. 2002;27:427–30.PubMedCrossRefGoogle Scholar
  29. 29.
    Jedrzejczak J, Dlawichowska E, Owczarek K, Majkowski J. Effect of vigabatrin addition on carbamazepine serum levels in patients with epilepsy. Epilepsy Res. 2000;39:115–20.PubMedCrossRefGoogle Scholar
  30. 30.
    Ragueneau-Majlessi I, Levy RH, Bergen D, Garnet W, Rosenfeld W, Mather G, Shah J, Grundy JS. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004;62:1–11.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • P. N. Patsalos
    • 1
    • 2
  1. 1.UCL-Institute of Neurology Department of Clinical and Experimental EpilepsyLondonLondon
  2. 2.Epilepsy Society Chalfont Centre for EpilepsyBuckinghamshireUK

Personalised recommendations